 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1213141516171819202122...208209» |
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Aidixi (disitamab vedotin) / Pfizer, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (EUDRACT) - Jan 31, 2026
P2, N=39, Not yet recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
- | 5-fluorouracil / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: Prospective, Dual-Cohort, Phase II Study of PD-L1 Inhibitor Combined with Gemcitabine and Nab-Paclitaxel Followed by Sequential PD-L1 Inhibitor Combined with Irinotecan Liposome, Oxaliplatin, and 5-FU/LV for Conversion Therapy in Borderline Resectable/Locally Advanced Pancreatic Cancer (EUDRACT) - Jan 31, 2026
P2, N=77, Not yet recruiting, Sponsor: Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University
- | AiRuiKa (camrelizumab) / Elevar Therapeutics, Focus V (anlotinib) / Advenchen
New P2 trial: ANCA trial: Anlotinib Plus Camrelizumab and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Phase II Trial (EUDRACT) - Jan 31, 2026
P2, N=56, Not yet recruiting, Sponsor: The General Hospital of the Western Theater Command of the Chinese People's Liberation Army; the General Hospital of the Western Theater Command of th
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
New P2 trial: SHR-A1811 plus QL1706 versus standard therapy as first-line treatment for locally advanced or metastatic HER2-overexpressing non-small cell lung cancer: an open-label, single-arm, phase II clinical trial (EUDRACT) - Jan 31, 2026
P2, N=39, Not yet recruiting, Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adbelimab combined with chemotherapy for perioperative treatment of resectable esophageal squamous cell carcinoma, exploring the representativeness of pathological responses in marking regional lymph nodes: A prospective, Phase II clinical stud (EUDRACT) - Jan 31, 2026
P2, N=35, Recruiting, Sponsor: Jiangsu Cancer Hospita; Jiangsu Cancer Hospita
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P2 trial: Trastuzumab rezetecan (SHR-A1811) combined with bevacizumab in previously treated HER2-altered non-small-cell lung cancer: a phase 2, single-arm study. (EUDRACT) - Jan 31, 2026
P2, N=60, Not yet recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Science; Cancer Hospital Chinese Academy of Medical Sciences
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P2 trial: Clinical study on the effect of henagliflozin proline combined with metformin on serum markers of cognitive impairment related to type 2 diabetes (EUDRACT) - Jan 31, 2026
P2, N=100, Not yet recruiting, Sponsor: Affiliated Hospital of Xuzhou Medical University, Xuzhou City, Jiangsu Province; Affiliated Hospital of Xuzhou Medical University
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study with Multiple Cohorts (EUDRACT) - Jan 31, 2026
P2, N=90, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined with Fruquintinib and Sodium Propionate Capsules for Late-Line Treatment of Advanced Metastatic Colorectal Cancer in a Phase II Study (EUDRACT) - Jan 31, 2026
P2, N=38, Not yet recruiting, Sponsor: The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: A Multicenter, Single-Arm Exploratory Clinical Study on the Efficacy and Safety of Herombopag Olamine Tablets in Patients with Breast Cancer Experiencing Thrombocytopenia Induced by T-DM1 (EUDRACT) - Jan 31, 2026
P2, N=56, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, iparomlimab (QL1604) / Qilu Pharma, Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
New P2 trial: Iparomlimab and Tuvonralimab in Combination with Nab-Paclitaxel and Apatinib as Second-Line Therapy for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: A Single-Center, Single-Arm IIT Study (EUDRACT) - Jan 31, 2026
P2, N=20, Not yet recruiting, Sponsor: Shanghai East Hospital; Shanghai East Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Exploratory Phase II Clinical Study of Adebrelimab Combined with Chemotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma (EUDRACT) - Jan 31, 2026
P2, N=44, Not yet recruiting, Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Single-Arm, Prospective Clinical Study of SBRT Sequential Aidebelimab Combined with Apatinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer (EUDRACT) - Jan 31, 2026
P2, N=29, Not yet recruiting, Sponsor: Xiamen Hospital of Zhongshan Hospital Affiliated to Fudan Un; Xiamen Hospital of Zhongshan Hospital Affiliated to Fudan Un
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab combined with irinotecan liposomal (ll), oxaliplatin, and 5-FU/LV conversion therapy for locally advanced pancreatic cancer: a prospective, single-arm, exploratory clinical study (EUDRACT) - Jan 31, 2026
P2, N=47, Recruiting, Sponsor: Jiangsu Provincial Hospital; Jiangsu Provincial Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: An Exploratory Study on the Treatment of Anaplastic Thyroid Carcinoma with Camrelizumab Combined with Apatinib and Capecitabine (EUDRACT) - Jan 31, 2026
P2, N=20, Completed, Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1316-202: A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer (EUDRACT) - Jan 31, 2026
P2, N=50, Completed, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P2 trial: A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HRS9531 injection in obese subjects with heart failure with preserved ejection fraction (EUDRACT) - Jan 31, 2026
P2, N=200, Recruiting, Sponsor: Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Capital Medical University
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Immunochemotherapy (EUDRACT) - Jan 31, 2026
P2, N=79, Recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Single-arm Phase II Clinical Trial evaluating Camrelizumab plus Capecitabine as Maintenance Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (EUDRACT) - Jan 31, 2026
P2, N=26, Recruiting, Sponsor: The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University
- | HRS-4642 / Jiangsu Hengrui Pharma
New P1/2 trial: HRS-4642-206: Phase IB/II clinical study of the safety, tolerability and efficacy of HRS-4642 in combination with other anti-tumor drugs in subjects with solid tumors (EUDRACT) - Jan 31, 2026
P1/2, N=60, Not yet recruiting, Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: Neoadjuvant PD-1 inhibitor plus chemotherapy and radiotherapy for potentially resectable locally advanced esophageal squamous cell carcinoma with esophageal fistula or high-risk for esophageal fistula: a single-arm phase I trial (EUDRACT) - Jan 31, 2026
P1, N=9, Recruiting, Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P1 trial: A Randomized Controlled Study of Fumarate Tegileridine versus Sufentanil for Postoperative Analgesia in Abdominal Surgery: A Comparison of Efficacy and Safety (EUDRACT) - Jan 31, 2026
P1, N=60, Not yet recruiting, Sponsor: The Second Affiliated Hospital of Xinjiang Medical University; The Second Affiliated Hospital of Xinjiang Medical University
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Enrollment open: Randomized, controlled and open label clinical trial of metformin Henagliflozin compound preparation in the treatment of type 2 diabetes mellitus patients with metabolic fatty liver disease and its effect on liver and pancreas fat content (EUDRACT) - Jan 31, 2026
P4, N=60, Recruiting, Sponsor: The First People's Hospital of Foshan; The First People's Hospital of Foshan
Not yet recruiting --> Recruiting
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A prospective clinical study on advanced or metastatic non-small cell lung cancer in the first-line treatment of adebelimab combined with emacetinib +/- chemotherapy (EUDRACT) - Jan 31, 2026
P4, N=68, Recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A prospective, exploratory clinical study of camrelizumab in combination with chemotherapy in the neoadjuvant treatment of monofocal or multifocal esophageal squamous cell carcinoma (EUDRACT) - Jan 31, 2026
P2, N=100, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Enrollment open: Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): a Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial (EUDRACT) - Jan 31, 2026
P=N/A, N=150, Recruiting, Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Enrollment open: Effect of remimazolam tosilate on Propofol-related Euphoria in upper gastrointestinal endoscopy:a prospective, randomized, double-blind, controlled clinical trial (EUDRACT) - Jan 31, 2026
P=N/A, N=600, Recruiting, Sponsor: Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || HRS-5965 / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: HRS-5965-103: Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment (clinicaltrials.gov) - Jan 31, 2026
P1, N=24, Completed, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Jan 2026
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
P3 data, Retrospective data, Journal: Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial. (Pubmed Central) - Jan 30, 2026
P3
Recruiting --> Completed | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Jan 2026 Vunakizumab has better efficacy than placebo with satisfactory safety profiles in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1?/CA9 signaling axis. (Pubmed Central) - Jan 30, 2026
This study elucidates a novel HDAC1/HIF1?/CA9 axis through which Apatinib induces ferroptosis. Targeting this pathway offers translational potential for overcoming Apatinib resistance in GC therapy.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Oncology, AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Journal, HEOR, Cost-effectiveness: Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer. (Pubmed Central) - Jan 30, 2026
Sensitivity analyses confirmed the robustness of these findings. Among the three domestic PD-1 inhibitors evaluated, camrelizumab is the most cost-effective first-line treatment option for advanced non-squamous NSCLC in China.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Clinical, P3 data, Retrospective data, Journal: Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial. (Pubmed Central) - Jan 30, 2026
The overall incidence of adverse events and most of the adverse events of special interest were similar between Ivarmacitinib and placebo across all subgroups. Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.
- | Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health, NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Preclinical, Journal: Effect of increasing chain length on inhibition of evaporation by perfluoro compounds in an in vitro gravimetric assay (no word/character limit specified). (Pubmed Central) - Jan 29, 2026
SFA chain length and volatility correlated with inhibition of the Revap of saline with the longest chain length SFAs F6H8 and F6H10 having the maximal effect. These data support the suitability of F6H8 as a treatment for evaporative dry eye disease.
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Journal: Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions. (Pubmed Central) - Jan 29, 2026
P3
These data support the suitability of F6H8 as a treatment for evaporative dry eye disease. Ivarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD.
- | cisplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, gemcitabine / Generic mfg.
Clinical, Journal: Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. (Pubmed Central) - Jan 29, 2026
P3
In this secondary analysis of a randomized clinical trial, the addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of RM-NPC. These findings provided the first 5-year evidence supporting the benefit of PD-1-based chemoimmunotherapy in this setting.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, birabresib (OTX015) / Merck (MSD)
Journal: The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia. (Pubmed Central) - Jan 29, 2026
5. SHR6390 and OTX015 Synergistically Inhibit the Growth of AML Xenografts In Vivo.
- | Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Retrospective data, Journal: No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 29, 2026
The present meta-analysis was registered in the International Prospective Register of Systematic Reviews (registration no. CRD420251084782).
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature. (Pubmed Central) - Jan 29, 2026
CRD420251084782). HAIC can treat high-bilirubin HCC with PVTT and OJ, allowing for subsequent targeted immunotherapy.
- |||| AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P2 trial: A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) (clinicaltrials.gov) - Jan 29, 2026
P2, N=120, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | zeprumetostat (SHR-2554) / Treeline Biosci, Duoenda (mitoxantrone liposomal) / CSPC Pharma
New P2 trial: Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (clinicaltrials.gov) - Jan 29, 2026
P2, N=26, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
- |||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
Enrollment open: SHR-8068-303: A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) (clinicaltrials.gov) - Jan 28, 2026
P3, N=604, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HAIC can treat high-bilirubin HCC with PVTT and OJ, allowing for subsequent targeted immunotherapy. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics
New P3 trial: Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jan 28, 2026
P3, N=200, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov) - Jan 28, 2026
P2, N=80, Active, not recruiting, Sponsor: Ruijin Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | cyclophosphamide / Generic mfg., plerixafor / Generic mfg., HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Retrospective data, Journal: Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On-Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort. (Pubmed Central) - Jan 28, 2026
In conclusion, CTX?+?PEG-rhG-CSF?+?on-demand PXF is a highly effective salvage mobilization strategy for patients with initial HSC mobilization failure, yielding higher CD34+ cell counts with fewer aphereses and acceptable safety. With balanced advantages in efficacy, safety, and cost-effectiveness, the CTX?+?PEG-rhG-CSF?+?on-demand PXF regimen can be a preferred salvage option for ASCT candidates with prior mobilization failure.
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Retrospective data, Journal: Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: a post-hoc analysis. (Pubmed Central) - Jan 28, 2026
P3
Patient-reported outcomes (PROs) at certain time points during 52?weeks were better in the vunakizumab group than in the placebo group. Vunakizumab is safe and effective in elderly patients with moderate-to-severe plaque psoriasis.
- | cyclophosphamide / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial. (Pubmed Central) - Jan 28, 2026
P2
Vunakizumab is safe and effective in elderly patients with moderate-to-severe plaque psoriasis. Patients in the experimental group receive Neo-DCVac (0.5-2
- || P2 data, Journal: Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. (Pubmed Central) - Jan 28, 2026
P2
The combination of inetetamab, camrelizumab, and utidelone demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with HER2-positive MBC. These findings support this regimen as a viable treatment option in this setting and warrant further investigation in randomized controlled trials.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) (clinicaltrials.gov) - Jan 27, 2026
P=N/A, N=244, Completed, Sponsor: First Hospital of China Medical University
These findings support this regimen as a viable treatment option in this setting and warrant further investigation in randomized controlled trials. Recruiting --> Completed
- ||||||| HR17031 / Jiangsu Hengrui Pharma
Trial completion: A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 27, 2026
P3, N=401, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 27, 2026
Camrelizumab combination therapy showed promising results in TNBC treatment, with good survival outcomes. Depending upon the outcomes of future phase III trials, factors influencing the efficacy of camrelizumab might be explored.